Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Apr 25, 2024
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
➞
Apr 11, 2024
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
➞
Apr 03, 2024
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
➞
Mar 25, 2024
Mabwell ranks on the list of 2024 Top 100 Hardcore Technology Enterprises in Shanghai
➞
Mar 18, 2024
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
➞
Mar 18, 2024
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
➞
Mar 15, 2024
Mabwell has been included in the FTSE Russell Global Equity Index Series
➞
Mar 11, 2024
Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London
➞
Mar 07, 2024
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
➞
Mar 06, 2024
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
➞
1
2
下一页